There were NOOOOOOO IDH mutant GBM (IV) patients in this trial. Zero.
There were four out of 15 methylated GBM patients in this trial. They were also the longest livers in the GBM set.
One was placebo (DCVax alone) and this patient lived to 61.2 months (so 5.1 years from beginning of treatment).
One was treatment with Poly ICLC (and DCVax) and this patient lived to 52.5 months (so 4.38 years from beginning of treatment)
Two were treatment with Resiquimod (and DCVax) and one patient lived to 16.1 months (so 1.34 years from beginning of treatment) second patient lived to 43.3 months (so 3.61 years from beginning of treatment)
See details below from the Patient Level Supplemental Chart found in the supplementary information. These were all the GBM patients in the trial. See relevant details below chart.
5. S23-64-3 GBM No IDH / No Methylated OS: 13.1 months
6. S26-59-3 GBM No IDH / No Methylated OS: 33.3 months
From the list of 5 Poly ICLC + DCVax-L patients, each of their OS were as follows: 24.5 26.6 28.6 median 28.6 52.5
So the median OS of the Poly ICLC GBM patients was 28.6, not 13... at least that's what the trial's patient level data shows. I think you were looking at the mPFS chart (not the mOS chart) when you accidentally pointed out that the mOS was 13. At least that's what it looks like to me when I looked at the chart (see below).